Paper36923535
First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod.
Starke L and 9 others. Theranostics, 2023. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod. Papers, record 36923535. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36923535
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Sclerosis | Major topic |
| Fluorine-19 Magnetic Resonance Imaging | Major topic |
| Multiple Sclerosis, Chronic Progressive | Major topic |
| Animals | |
| Mice | |
| Pharmaceutical Preparations | |
| Magnetic Resonance Imaging | |
| Sphingosine-1-Phosphate Receptors | |
| Azetidines | |
| Benzyl Compounds |
Source PubMed
References100
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10617435 | An analytical derivation of a popular approximation of the Voigt function for quantification of NMR spectra. | J Magn Reson | 2000 | https://conductscience.org/library/papers/10617435 | PubMed |
| 2 | 34812528 | B1 inhomogeneity correction of RARE MRI at low SNR: Quantitative in vivo 19 F MRI of mouse neuroinflammation with a cryogenically-cooled transceive surface radiofrequency probe. | Magn Reson Med | 2022 | https://conductscience.org/library/papers/34812528 | PubMed |
| 3 | 11264465 | Metabolism of fluorine-containing drugs. | Annu Rev Pharmacol Toxicol | 2001 | https://conductscience.org/library/papers/11264465 | PubMed |
| 4 | 26794270 | From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. | Nat Rev Drug Discov | 2016 | https://conductscience.org/library/papers/26794270 | PubMed |
| 5 | 32722245 | Does Siponimod Exert Direct Effects in the Central Nervous System? | Cells | 2020 | https://conductscience.org/library/papers/32722245 | PubMed |
| 6 | 16767752 | High magnetic field water and metabolite proton T1 and T2 relaxation in rat brain in vivo. | Magn Reson Med | 2006 | https://conductscience.org/library/papers/16767752 | PubMed |
| 7 | 23939898 | Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23939898 | PubMed |
| 8 | 24639022 | Optimized three-dimensional sodium imaging of the human heart on a clinical 3T scanner. | Magn Reson Med | 2015 | https://conductscience.org/library/papers/24639022 | PubMed |
| 9 | 20842758 | Fluorine (19F) MRS and MRI in biomedicine. | NMR Biomed | 2011 | https://conductscience.org/library/papers/20842758 | PubMed |
| 10 | 17969013 | Sparse MRI: The application of compressed sensing for rapid MR imaging. | Magn Reson Med | 2007 | https://conductscience.org/library/papers/17969013 | PubMed |
| 11 | 29576505 | Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. | Lancet | 2018 | https://conductscience.org/library/papers/29576505 | PubMed |
| 12 | 27990708 | Temporal accumulation and localization of isoflurane in the C57BL/6 mouse and assessment of its potential contamination in 19 F MRI with perfluoro-crown-ether-labeled cardiac progenitor cells at 9.4 Tesla. | J Magn Reson Imaging | 2017 | https://conductscience.org/library/papers/27990708 | PubMed |
| 13 | 31821174 | Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury. | JCI Insight | 2020 | https://conductscience.org/library/papers/31821174 | PubMed |
| 14 | 15509509 | The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. | Mol Ther | 2004 | https://conductscience.org/library/papers/15509509 | PubMed |
| 15 | 33456555 | In vivo detection of teriflunomide-derived fluorine signal during neuroinflammation using fluorine MR spectroscopy. | Theranostics | 2021 | https://conductscience.org/library/papers/33456555 | PubMed |
| 16 | 24900670 | Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. | ACS Med Chem Lett | 2013 | https://conductscience.org/library/papers/24900670 | PubMed |
| 17 | 23227121 | Image guided biodistribution and pharmacokinetic studies of theranostics. | Theranostics | 2012 | https://conductscience.org/library/papers/23227121 | PubMed |
| 18 | 17627846 | Morphometric analysis of the C57BL/6J mouse brain. | Neuroimage | 2007 | https://conductscience.org/library/papers/17627846 | PubMed |
| 19 | 34911793 | Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis. | Neurol Neuroimmunol Neuroinflamm | 2022 | https://conductscience.org/library/papers/34911793 | PubMed |
| 20 | 27380540 | Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. | JAMA Neurol | 2016 | https://conductscience.org/library/papers/27380540 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42942759 | Drug Delivery Vehicle-Teriflunomide Interactions Affect Treatment and Fluorine Magnetic Resonance in an Animal Model of Multiple Sclerosis. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42942759 | PubMed |
| 41356192 | Translational molecular imaging and drug development in multiple sclerosis. | Theranostics | 2026 | https://conductscience.org/library/papers/41356192 | PubMed |
| 40993945 | FDA-Approved Fluorine-Containing Molecules in 2024: Significance, Synthesis, and Therapeutic Applications. | Curr Top Med Chem | 2026 | https://conductscience.org/library/papers/40993945 | PubMed |
| 40182047 | Identifying new therapeutics for focused ultrasound-enhanced drug delivery in the management of glioblastoma. | Front Oncol | 2025 | https://conductscience.org/library/papers/40182047 | PubMed |
| 38865057 | MR beyond diagnostics at the ESMRMB annual meeting: MR theranostics and intervention. | MAGMA | 2024 | https://conductscience.org/library/papers/38865057 | PubMed |
| 37190232 | Advanced Radio Frequency Applicators for Thermal Magnetic Resonance Theranostics of Brain Tumors. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37190232 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| S1PR1 | 1901 | PubTator's text mining | https://conductscience.org/library/genes/1901 | NCBI Gene |
| S1PR5 | 53637 | PubTator's text mining | https://conductscience.org/library/genes/53637 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36923535
GET https://conductscience.org/api/papers/v1/36923535/references?page=2